Frank Westermann sold his previous startup, mySugr, to Roche four years ago. Now, he’s starting a new company with the goal of making healthcare providers and diabetes medications more accessible.
mySugr cofounder and CEO Frank Westermann responds to questions about the recent acquisition of his smartphone-enabled diabetes management business and what will come next.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The acquisition fits into a growing trend of pharma and medical device companies adding services supporting patient engagement both to quantify and improve the effectiveness of their drugs and devices and to gain additional insight from their customer base.
A look at some of the hidden challenges of diabetes management and how the patient experience can be improved.
Both groups will jointly design and execute a development program to enhance and validate the clinical and health economic impact of mySugr’s diabetes management apps.
The marketing collaboration will be rolled out on a country by country basis, starting with Germany and Austria, followed by the U.S.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Optical character recognition could offer an alternative to Internet of Things to transmit vital health data to physicians.
mySugr Importer (English) from mySugr on Vimeo. mySugr is a diabetes app developer that’s striving to set itself apart from other direct-to-consumer mobile health companies for chronic conditions. Its apps are intended to strike a balance between relevant and important information for its users with colorful graphics and a gaming component. With a $4.8 million […]